Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Circulation
Mikhail KosiborodCVD-REAL Investigators and Study Group*

Abstract

Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries to determine if these benefits are seen in real-world practice and across SGLT-2i class. Data were collected via medical claims, primary care/hospital records, and national registries from the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom. Propensity score for SGLT-2i initiation was used to match treatment groups. Hazard ratios for HHF, death, and their combination were estimated by country and pooled to determine weighted effect size. Death data were not available for Germany. After propensity matching, there were 309 056 patients newly initiated on either SGLT-2i or other glucose-lowering drugs (154 528 patients in each treatment group). Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%, and 5% of the total exposure time in the SGLT-2i class, respectively. Baseline characteristics were balanced between...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jul 1, 1974·The American Journal of Cardiology·W B KannelW P Castelli
Feb 28, 2004·Diabetes Care·Alain G BertoniDavid C Goff
May 27, 2005·European Journal of Heart Failure·Erik IngelssonLars Lind
Jan 13, 2006·Biometrics·Ross L PrenticeGarnet L Anderson
Jun 10, 2008·European Journal of Heart Failure·Thomas KümlerChristian Torp-Pedersen
Sep 28, 2010·Statistical Science : a Review Journal of the Institute of Mathematical Statistics·Elizabeth A Stuart
Jun 11, 2011·BMC Public Health·Jonas F LudvigssonPetra Otterblad Olausson
Sep 29, 2011·Clinical Trials : Journal of the Society for Clinical Trials·Miguel A Hernán, Sonia Hernández-Díaz
Mar 20, 2013·Diabetes Research and Clinical Practice·UNKNOWN IDF Diabetes Atlas Group
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 8, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 22, 2015·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Jon BrynildsenHelge Røsjø
Oct 29, 2015·The New England Journal of Medicine·Mauro TancrediMarcus Lind
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Dec 16, 2016·The New England Journal of Medicine·Robert M CaliffRachel E Sherman
Mar 1, 2017·Diabetes, Obesity & Metabolism·Bruce NealUNKNOWN CANVAS Program collaborative group

❮ Previous
Next ❯

Citations

Jan 4, 2018·Postgraduate Medicine·Robert Guthrie
Jan 27, 2018·European Journal of Endocrinology·Russell L EsterlineJiten Vora
Mar 9, 2018·Diabetes, Obesity & Metabolism·Gian Paolo FadiniUNKNOWN DARWIN-T2D network
Apr 1, 2018·Diabetes, Obesity & Metabolism·Salvatore CarboneAntonio Abbate
Jan 11, 2018·Diabetes/metabolism Research and Reviews·Angelo AvogaroIldiko Lingvay
Jan 24, 2018·Heart Failure Reviews·Alberto PalazzuoliRanuccio Nuti
Apr 29, 2018·Heart Failure Reviews·Joaquim Silva CustodioLeonardo Roever
Jul 12, 2017·Journal of Diabetes·Andrew Drexler
May 17, 2018·Clinical and Translational Science·Brandon SwiftPravin R Jadhav
Nov 3, 2017·Current Heart Failure Reports·Amanda Trang, David Aguilar
May 23, 2018·Journal of Diabetes·Ann M CarracherKelly L Close
May 24, 2018·Expert Opinion on Pharmacotherapy·Kashif M Munir, Stephen N Davis
Sep 8, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Dec 14, 2017·European Heart Journal·Haitham M AhmedLeslie Cho
May 12, 2018·Clinical and Experimental Pharmacology & Physiology·Tushar MadaanAbul Kalam Najmi
Jun 19, 2018·The Annals of Pharmacotherapy·Joseph E CruzMary Barna Bridgeman
May 24, 2018·Journal of Diabetes·Ann M CarracherKelly L Close
Jan 31, 2018·Current Medical Research and Opinion·Anna D CoutinhoStephen D Sander
Jul 22, 2018·Diabetes/metabolism Research and Reviews·Annunziata NuscaGermano Di Sciascio
Jul 14, 2018·Diabetes, Obesity & Metabolism·Emanuel RaschiFabrizio De Ponti
Jul 25, 2018·Diabetes, Obesity & Metabolism·Ghadeer K DawwasHaesuk Park
Sep 18, 2018·Scandinavian Journal of Public Health·Marit Eika JørgensenBendix Carstensen
Aug 24, 2018·Diabetes, Obesity & Metabolism·Suzanne V ArnoldMikhail Kosiborod
Jul 19, 2017·Circulation·Anushka Patel, Laurent Billot

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02993614
NCT01032629
NCT01730534
NCT01986881

Software Mentioned

MarketScan
REG
CVD
Statisticon
REAL
Match
package Matching
R

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.